Panbela Therapeutics, Inc.
PBLA
$0.2603
-$0.0607-18.91%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 0.54% | -32.68% | -10.95% | -45.07% | -14.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.68% | 37.88% | 38.40% | 35.96% | 116.56% |
| Operating Income | 8.68% | -37.88% | -38.40% | -35.96% | -116.56% |
| Income Before Tax | 8.64% | -19.38% | -41.95% | -36.78% | -76.09% |
| Income Tax Expenses | -- | -- | -- | -58.33% | 66.07% |
| Earnings from Continuing Operations | 8.42% | -22.39% | -39.25% | -36.73% | -77.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.42% | -22.39% | -39.25% | -36.73% | -77.90% |
| EBIT | 8.68% | -37.88% | -38.40% | -35.96% | -116.56% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 97.25% | 99.08% | 99.42% | -- | -- |
| Normalized Basic EPS | 97.39% | 99.00% | 99.41% | -- | -- |
| EPS Diluted | 97.25% | 99.08% | 99.42% | -- | -- |
| Normalized Diluted EPS | 97.39% | 99.00% | 99.41% | -- | -- |
| Average Basic Shares Outstanding | 3,232.12% | 13,128.61% | 23,944.62% | -- | -- |
| Average Diluted Shares Outstanding | 3,232.12% | 13,128.61% | 23,944.62% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |